Faron Pharma secures UK innovation passport for blood cancer immunotherapy
Faron Pharmaceuticals is advancing its cancer immunotherapy programme in the UK, with the region’s regulatory authorities approving the advancement of …
Post
-
-
Fate Therapeutics makes Bob Valamehr president and CEO
Fate Therapeutics has announced the retirement of president and CEO Scott Wolchko on 31 December 2024, with current research and development …
-
CHMP recommends oral peanut allergy immunotherapy treatment for toddlers
The European Medicines Agency’s (EMAs) Committee for Medicinal Products for Human Use (CHMP) has recommended extending the use of Stallergenes …
-
CBC acquires UCB’s neurology and allergy business in China
CBC Group, in partnership with the Mubadala Investment Company, has completed the strategic acquisition of Union Chimique Belge's (UCB) mature …
-
UQ secures funds for development of skin cancer prevention cream
A research team at Australia's University of Queensland (UQ) has secured a A$344,000 grant from the National Foundation for Medical …
-
PrEP therapies offer new hope in HIV preventive landscape as vaccine failures amass
Research activity in the human immunodeficiency viruses space (HIV) is pivoting towards pre-exposure prophylaxis (PrEP) therapies as vaccine failures rack …
-
EMA launches ESMP for better management of drug shortages in EU
The first version of the European Shortages Monitoring Platform (ESMP) has gone live to help marketing authorisation holders (MAHs) report …
-
University of Birmingham identifies target to reduce GVHD risk
The University of Birmingham researchers have identified CD70 as a key target to reduce the risk of graft-versus-host disease (GVHD) …
-
UK Government to launch first ever men’s health strategy
As Men’s Health Awareness Month comes to an end, UK Health Secretary Wes Streeting has announced the development of a …
-
UK reports near eradication of meningitis C amid declining vaccine uptake
New data from the UK Health Security Agency (UKHSA) indicates significant progress in combating meningitis caused by meningococcal group C …
-
Allink Biotherapeutics secures funding to advance ADC pipeline
Allink Biotherapeutics has completed a $42m Series A financing round to expedite the worldwide development of its bispecific antibody and …
-
Formosa and Medvisis agree on post-operative eye pain therapy
Formosa Pharmaceuticals in Taiwan has signed an exclusive licensing agreement with Medvisis Switzerland to commercialise clobetasol propionate ophthalmic suspension, 0.05% …
-
Trump 2.0 spells global change in pharmaceutical regulation, funding and investment
Having promised to “Make America Healthy Again”, the administration in Trump’s second presidency looks set to shake up the health …
-
Advanz Pharma’s liver disease drug pulled from European market after court hearing
Advanz Pharma’s liver disease drug Ocaliva (obeticholic acid) will no longer be available in Europe after the General Court of …
-
Kronos Bio announces interim CEO and workforce cuts of 83%
Kronos Bio has announced the appointment of Deborah Knobelman as president and interim chief executive officer, effective from 3 December …
